Media coverage about China Cord Blood (NYSE:CO) has been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. China Cord Blood earned a news impact score of 0.23 on Accern’s scale. Accern also assigned media headlines about the medical research company an impact score of 47.2252093796326 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Shares of China Cord Blood (NYSE CO) opened at $10.52 on Tuesday. The firm has a market cap of $1,268.75, a price-to-earnings ratio of 30.06 and a beta of 0.91. China Cord Blood has a twelve month low of $5.06 and a twelve month high of $14.95.
China Cord Blood (NYSE:CO) last posted its earnings results on Monday, November 20th. The medical research company reported $0.09 earnings per share for the quarter. The company had revenue of $35.26 million for the quarter. China Cord Blood had a net margin of 26.79% and a return on equity of 9.68%.
About China Cord Blood
China Cord Blood Corporation is a provider of cord blood banking services in China. The Company and its subsidiaries are principally engaged in the provision of umbilical cord blood storage and ancillary services in the People’s Republic of China. It provides cord blood testing, processing and storage services under the direction of subscribers for a cord blood processing fee and a storage fee.
Receive News & Ratings for China Cord Blood Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Cord Blood and related companies with MarketBeat.com's FREE daily email newsletter.